Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Psilocybin/Personality & Trait Factors

Psilocybin for Personality & Trait Factors

44 papers and 1 clinical trial exploring psilocybin as a treatment for personality & trait factors.

CompoundClassic Psychedelic

Psilocybin

Psilocybin is a naturally occurring tryptamine psychedelic that acts as a prodrug to psilocin, a potent 5-HT2A receptor agonist. It is the furthest advanced psychedelic in clinical development, with two positive Phase III trials in treatment-resistant depression and expanding regulated access in Australia, Germany, and US states.

Full Psilocybin profile
IndicationApproximately 10 million adults in the UK suffer from a personality disorder.

Personality & Trait Factors

Psychedelic research is increasingly examining the interplay between personality traits and therapeutic outcomes in various mental health conditions. Recent studies highlight how certain personality traits may influence the efficacy of psychedelic treatments, particularly in managing disorders like depression and anxiety.

Full Personality & Trait Factors profile

Academic Research

44 papers
Open Accessindividual

Effects of psychedelic use on authoritarian attitudes revisited

This re-analysis of three studies found no clear change in authoritarian attitudes after psychedelic use, including in people who planned to take psychedelics, healthy volunteers given psilocybin, and patients with depression in a randomised trial.

Published
May 2, 2026
Journal
Journal of Psychopharmacology
Authors
Simonsson, O., Lyons, T., Marks, J., Kettner, H., Roseman, L., Haijen, E., Kaelen, M., Carhart-Harris, R.
Open Accessindividual

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study

This double-blind, randomised, placebo-controlled Phase I study (n=48) evaluates the safety, pharmacokinetics, and psychoactive effects of RE104 (psilocybin analog; Luvesilocin; a prodrug of 4-OH-DiPT) in healthy adults with prior psychedelic experience. RE104 was well tolerated up to 40 mg with no serious adverse events, and plasma levels of its active form correlated with subjective drug effect and mystical experience scores. The compound produced psilocybin-like effects with a shorter duration (3-4 hours), supporting further therapeutic investigation.

Published
July 21, 2025
Journal
Journal of Clinical Psychopharmacology
Authors
Ludbrook, G., Bryson, N., Taylor, B., Hocevar-Trnka, J., Johnson, M. W., Hirman, J., Morrish, G., Alexander, R., Pollack, M.
Open Accessindividual

Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation

In a naturalistic, open‑label study a single high dose of psilocybin with psychotherapy produced sustained reductions in depression, anxiety, PTSD symptoms and neuroticism, and increases in openness and conscientiousness at three months. The size of these benefits was moderated by participants’ subjective dosing experiences (mystical‑type experiences, emotional breakthrough and post‑treatment growth) and demographic factors, highlighting variables that may help optimise psilocybin‑assisted treatment.

Published
January 7, 2025
Journal
Psychopharmacology
Authors
Irrmischer, M., Puxty, D. J., Deijen, J. B., Engelbregt, H., Yildirim, B. O.
Open Accessindividual

An investigation of acute Physiological and Psychological Moderators of Psychedelic-induced Personality Change among Healthy Volunteers

This re-analysis of a single-blind, fixed-order trial (n=28) investigates the effects of a single high-dose psilocybin (25 mg) on personality traits in psychedelic-naïve healthy volunteers. It finds significant reductions in neuroticism one month post-administration, moderated by subjective experience meaningfulness and ego dissolution, suggesting psilocybin catalyses lasting personality changes with therapeutic potential.

Published
January 1, 2025
Journal
Neuroscience Applied
Authors
Godfrey, K., Weiss, B., Zhang, X., Spriggs, M. J., Peill, J. M., Lyons, T., Carhart-Harris, R. L., Erritzoe, D.
Open Accessindividual

Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial

This secondary of a Phase II study (n=84) investigates the effects of psilocybin-assisted therapy (PAT) on personality traits in alcohol use disorder (AUD). Psilocybin (2x, 25-40mg/70kg; n=44) significantly reduced neuroticism and increased extraversion and openness compared to placebo (diphenhydramine, n=40). Decreased impulsiveness correlated with lower alcohol consumption post-treatment, suggesting PAT may normalize abnormal personality traits in AUD.

Published
January 1, 2025
Journal
American Journal of Psychiatry
Authors
Pagni, B. A., Zeifman, R. J., Mennenga, S. E., Carrithers, B. M., Goldway, N., Bhatt, S. R., O'Donnell, K., Ross, S., Bogenschutz, M. P.
Paywallindividual

Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy

This technical report (2024) describes the evolving guidelines for facilitator use of touch in a group retreat-based format of psilocybin-assisted therapy. The primary goal is to create a safe and supportive haptic experience during sessions, with a secondary goal of maintaining therapeutic boundaries and responding to participant experiences with empathy.

Published
December 1, 2024
Journal
Psychedelic Medicine
Authors
Back, A., Myers, S., Guy, J., Perez, J., Thorn, L. L., Mcgregor, B.

Clinical Trials

1 trial
Completed

Psilocybin-Assisted Treatment Naturalistic Observational Study: Mood and Personality Moderators (Irrmischer / Engelbregt, Netherlands 2025)

This unregistered trial (n=83) was an open-label, naturalistic observational study of psilocybin-assisted treatment for depression, anxiety, and PTSD in self-referred participants, which found that subjective experiences and demographic factors moderated improvements in mood and personality.

Started
January 1, 2020
Type
interventional
Randomized
No
Registry ID
IRRMISCHER-2025-PSYCHOPHARMACOL-PSILOCYBIN-NATURALISTIC-NL

Explore further

Search all Psilocybin papers Search all Personality & Trait Factors trials Full Psilocybin profile Full Personality & Trait Factors profile